EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

A treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT ‐5 trial

Carel W le Roux iD, Luca Busetto, Louis Aronne iD, Deborah Bade Horn, Georgios K Dimitriadis, Beverly Falcon, Luis-Emilio Garcia-Perez iD, Elisa Gomez Valderas, Theresa Hunter Gibble iD, Cagri Senyucel, Julia P Dunn iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70531 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Carel W le Roux und 10 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Obesity Management. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

With new advancements in obesity medicine, clarity on goals and expectations for successful disease management is limited. This post hoc analysis assessed application of proposed treat‐to‐target (TtT) thresholds for obesity to the outcome measures of SURMOUNT‐5, which randomised participants with obesity to tirzepatide or semaglutide.

Methods

The proportion of participants in each treatment group reaching proposed TtT thresholds for waist to height ratio (WHtR)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityObesity ManagementAdultFemaleHumansMaleMiddle AgedBody Mass IndexSemaglutideTirzepatideTreatment OutcomeWeight LossRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

cardiometabolic measuresobesityobesity managementtirzepatidetreat‐to‐targetwaist to height ratio

Substanzen

Anti-Obesity AgentsSemaglutideTirzepatide

Autor:innen und Institutionen

  • Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.
  • Diabetes Research Centre, Ulster University, Coleraine, UK.
  • Department of Medicine, University Hospital of Padova, Padova, Italy.
  • Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York, New York, USA.
  • Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston, Texas, USA.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Carel W le Roux, Louis Aronne, Luis-Emilio Garcia-Perez, Theresa Hunter Gibble, Julia P Dunn

Förderung

  • Eli Lilly and Company

Zitieren

APA

le Roux, C. W., Busetto, L., Aronne, L., Horn, D. B., Dimitriadis, G. K., Falcon, B., Garcia-Perez, L. E., Valderas, E. G., Gibble, T. H., Senyucel, C., & Dunn, J. P. (2026). A treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT ‐5 trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70531

Vancouver

le Roux CW, Busetto L, Aronne L, Horn DB, Dimitriadis GK, Falcon B, et al. A treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT ‐5 trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70531

BibTeX
@article{leRoux2026,
  author = {le Roux, Carel W and Busetto, Luca and Aronne, Louis and Horn, Deborah Bade and Dimitriadis, Georgios K and Falcon, Beverly and Garcia-Perez, Luis-Emilio and Valderas, Elisa Gomez and Gibble, Theresa Hunter and Senyucel, Cagri and Dunn, Julia P},
  title = {A treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT ‐5 trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70531}
}
Kostenlos starten →